Myclausen (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myclausen, is an antimetabolite immunosuppressant presented as an oral formulation for oral use and marketed in the European Union. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing immune cell proliferation.

GNH USA supplies Myclausen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with a focus on quality assurance and regulatory compliance.

Myclausen (mycophenolate mofetil) is used in immunosuppressive therapy for specific transplant and autoimmune conditions. - Kidney transplant: helps prevent graft rejection by inhibiting lymphocyte proliferation. - Heart transplant: reduces risk of organ rejection through immune suppression. - Liver transplant: supports maintenance of graft function by limiting immune response. - Lupus nephritis: improves renal outcomes by decreasing autoimmune inflammation.

Myclausen may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial pain. - Infections: increased susceptibility to common infections.

Serious or Rare Side Effects: - Bone marrow suppression: anemia, leukopenia, thrombocytopenia. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe infections: opportunistic or systemic infections. - Malignancy risk: increased incidence of certain cancers.

When prescribing Myclausen, clinicians should consider several precautionary measures to minimize risk. - Monitor blood counts: regular CBC to detect bone marrow suppression. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate renal function: dose adjustments may be needed in impaired kidneys. - Avoid live vaccines: increased infection risk while immunosuppressed. - Review concomitant medications: potential drug interactions may increase toxicity. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Myclausen can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of mycophenolate. - Azathioprine: additive bone marrow suppression. - Cyclosporine or tacrolimus: increased mycophenolate exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, decreasing drug levels. - Valganciclovir: may increase risk of cytopenias. - Cholesterol‑lowering agents (e.g., statins): potential for increased mycophenolate concentrations.